Matthew R. Grace

Matthew R. Grace

Auto-generated profile, based on publicly available information

Matthew R. Grace

Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Food and Chemical Toxicology
Verified
Journal Article
Open access
SBSamira A. Brooks
Samira A. Brooks
EMElizabeth Martin
Elizabeth Martin
LSLisa Smeester
Lisa Smeester
MGMatthew R. Grace
Matthew R. Grace
KBKim Boggess
Kim Boggess
RFRebecca C Fry
Rebecca C Fry
Preeclampsia (PE) is a pregnancy disorder characterized by high blood pressure and proteinuria that can cause adverse health effects in both mother and fetus. There is no current cure for PE other than delivery of the fetus/placenta. While the etiology is unknown, poor placentation due to aberrant signaling of growth and angiogenic factors has been postulated as a causal factor of PE. In addition, environmental contaminants, such as the metal cadmium (Cd), have been linked to placental toxicity and increased risk of developing PE. Here, we use a translational study design to investigate genomic and epigenomic alterations in both placentas and placental trophoblasts, focused on the angiogenesis-associated transforming growth factor-beta (TGF-β) pathway. Genes within the TGF-β pathway displayed increased expression in both the preeclamptic placenta and Cd-treated trophoblasts. In addition, miRNAs that target the TGF-β pathway were also significantly altered within the preeclamptic placenta and Cd-treated trophoblasts. Integrative analysis resulted in the identification of a subset of Cd-responsive miRNAs, including miR-26a and miR-155, common to preeclamptic placentas and Cd-treated trophoblasts. These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-β pathway. Results from this study provide future targets for PE treatment.

1 July 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MGMatthew R. Grace
Matthew R. Grace
EHEmily Hardisty
Emily Hardisty
NGNoah S. Green
Noah S. Green
EDEmily Davidson
Emily Davidson
ASAlison M. Stuebe
Alison M. Stuebe
NVNeeta Vora
Neeta Vora

1 March 2024 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
BGBrighton S. Ms Goodhue
Brighton S. Ms Goodhue
SDSky E. Danity
Sky E. Danity
NVNeeta Vora
Neeta Vora
JKJeffrey A. Kuller
Jeffrey A. Kuller
MGMatthew R. Grace
Matthew R. Grace
Importance: In pregnancy, cell-free DNA (cfDNA) represents short fragments of placental DNA released into the maternal blood stream through natural cell death. Noninvasive prenatal screening with cfDNA is commonly used in pregnancy to screen for common aneuploidies. This technology continues to evolve, and laboratories now offer cfDNA screening for single-gene disorders. Objective: This article aims to review cfDNA screening for single-gene disorders including the technology, current syndromes for which screening may be offered, limitations, and current recommendations. Evidence Acquisition: Original research articles, review articles, laboratory white papers, and society guidelines were reviewed. Results: Cell-free DNA screening for single-gene disorders is not currently recommended by medical societies. There may be a role in specific circumstances and only after comprehensive pretest counseling. It can be considered in the setting of some fetal ultrasound anomalies, and usually only after diagnostic testing is offered and declined. Conclusions: Given the limitations of using cfDNA screening for single-gene disorders, caution is recommended when considering these tests. It should only be offered with involvement of a reproductive genetic counselor, medical geneticist, or maternal fetal medicine specialist to ensure comprehensive counseling and appropriate utilization. Target Audience: Obstetricians and gynecologists, family medicine physicians Learning Objectives: After completing this reading, learners should be able to describe how laboratories have expanded cfDNA screening beyond common aneuploidy screening; explain the differences between disorders caused by aneuploidy, copy number variants, and single-gene changes; identify patient populations that may be at increased risk for single-gene disorders and the limitations of cfDNA screening for the disorders; and discuss when to refer a patient to a genetic counselor or maternal fetal medicine specialist if a patient requests cfDNA screening for a single-gene disorder.

5 March 2023 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
EGErin Griffin
Erin Griffin
GHGillian Hooker
Gillian Hooker
MGMatthew Grace
Matthew Grace
KKKimberly A. Kaphingst
Kimberly A. Kaphingst
DEDigna Velez Edwards
Digna Velez Edwards
JSJill Slamon
Jill Slamon

30 December 2024 in Current Opinion in Obstetrics and Gynecology
Verified
Journal Article
Closed access
MGMatthew R. Grace
Matthew R. Grace
BGBrighton Goodhue
Brighton Goodhue
NVNeeta L. Vora
Neeta L. Vora
Purpose of review: Despite the availability of Rh(D) immune globulin (RhIg) to prevent alloimmunization in Rh(D)-negative pregnant patients, anti-Rh(D) alloimmunization remains a prevalent cause of hemolytic disease of the fetus and newborn (HDFN). Recent RhIg shortages have caused clinicians and professional societies to identify methods to prioritize RhIg administration. New cell-free DNA (cfDNA) tests to predict fetal red blood cell antigen genotypes have been proposed as an option to prioritize the administration of RhIg to Rh(D)-negative pregnant people. Recent findings: Commercial laboratories offer fetal Rh(D) genotype testing as part of cfDNA screening for fetal aneuploidy. Studies indicate that these tests have a high sensitivity and specificity for the detection of fetal Rh(D) status. Considering the current RhIg shortage, the American College of Obstetricians & Gynecologists (ACOG) suggests that utilizing cfDNA tests to determine fetal Rh(D) status is a reasonable approach to prioritize RhIg administration when supply is limited. Summary: cfDNA screening for fetal Rh(D) status is a reasonable approach to triage the administration of RhIg in the setting of the current RhIg shortage. Utilization of cfDNA screening for fetal Rh(D) and other red blood cell antigen status is likely to increase in routine care. Research, professional society guidance, and education are necessary to ensure well tolerated and equitable utilization.

13 May 2023 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
GNGabriela Rafaelle Chayah Nisly
Gabriela Rafaelle Chayah Nisly
JDJacquelyn L. Dillon
Jacquelyn L. Dillon
ADAlice Darling
Alice Darling
SMSabrena Myers
Sabrena Myers
NSNoor Al Shibli
Noor Al Shibli
SDSarah K. Dotters-Katz
Sarah K. Dotters-Katz
Objective This study aimed to characterize rates of maternal morbidity associated with early (2 units were considered severe maternal morbidity (SMM). Simple statistics used to compare characteristics among patients experiencing any morbidity and those not. Poisson regression used to assess relative risks. Results Of 260 patients included, 77 (29.6%) experienced maternal morbidity and 16 (6.2%) experienced severe morbidity. PPH (n = 46, 17.7%) was the most common morbidity, although 15 (5.8%) patients were readmitted, 16 (6.2%) needed a blood transfusion, and 14 (5.4%) had AKI. Patients who experienced maternal morbidity were more likely to be advanced maternal age, have preexisting diabetes, have multiples, and deliver nonvaginally (all ps < 0.05). Diagnosis of preeclampsia < 28 weeks or longer latency from diagnosis to delivery were not associated with increased maternal morbidity. In regression models, the relative risk of maternal morbidity remained significant for twins (adjusted odds ration [aOR]: 2.57; 95% confidence interval [CI]: 1.67, 3.96) and preexisting diabetes (aOR: 1.64; 95% CI: 1.04, 2.58), whereas attempted vaginal delivery was protective (aOR: 0.53; 95% CI: 0.30, 0.92). Conclusion In this cohort, more than 1 in 4 patients diagnosed with early preeclampsia with severe features experienced maternal morbidity, whereas 1 in 16 patients experienced SMM. Twins and pregestational diabetes were associated with higher risk of morbidity, whereas attempted vaginal delivery was protective. These data may be helpful in promoting risk reduction and counseling patients diagnosed with early preeclampsia with severe features. Key Points